Navigation Links
Nano drug crosses blood-brain tumor barrier, targets brain-tumor cells and blood vessels
Date:7/17/2013

  • The blood-brain barrier protects the brain from poisons but also prevents drugs from reaching brain tumors; innovative new treatments are needed.
  • This laboratory study shows that a nanotechnology drug called SapC-DOPS crosses that barrier and targets brain-tumor cells and retards growth of tumor blood vessels.
  • The findings also show how the agent targets tumor cells and recommend its further development as a novel treatment for glioblastoma.

COLUMBUS, Ohio An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels. The findings support further development of the drug as a novel treatment for brain tumors.

Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months. A major obstacle to improving treatment for the 3,470 cases of the disease expected in the United States this year is the blood-brain barrier, the name given to the tight fit of cells that make up the blood vessels in the brain. That barrier protects the brain from toxins in the blood but also keeps drugs in the bloodstream from reaching brain tumors.

"Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells," says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC James. "Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors."

The findings were published in a recent issue of the journal Molecular Therapy.

SapC-DOPS (saposin-C dioleoylphosphatidylserine), is a nanovesicle drug that has shown activity in glioblastoma, pancreatic cancer and other solid tumors in preclinical studies. The nanovesicles fuse with tumor cells, causing them to self-destruct by apoptosis.

Key findings of the study, which used two brain-tumor models, include:

  • SapC-DOPS binds with exposed patches of the phospholipid phosphatidylserine (PtdSer) on the surface of tumor cells;
  • Blocking PtdSer on cells inhibited tumor targeting;
  • SapC-DOPS strongly inhibited brain-tumor blood-vessel growth in cell and animal models, probably because these cells also have high levels of exposed PtdSer.
  • Hypoxic cells were sensitized to killing by SapC-DOPS.

"Based on our findings, we speculate that SapC-DOPS could have a synergistic effect when combined with chemotherapy or radiation therapy, both of which are known to increase the levels of exposed PtdSer on cancer cells," Kaur says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. A new European network crosses the boundaries for excellence in language and perception research
2. E-Store India Crosses the 1-million Mark for Number of Registered Online Buyers
3. Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy
4. Improved Stem Cell Line May Avoid Tumor Risk: Study
5. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
8. Brain Tumor Vaccine Shows Promise in Early Trial
9. Kidney Cancer Patients Fare Better With Tumor Removal Only
10. IBN discovers human neural stem cells with tumor targeting ability
11. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic dentist in ... is among the most popular cosmetic procedures in dentistry today, but the cost often ... put them at risk of teeth whitening-related damage. For a limited time, Dr. Rassouli ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... to create “Ebola: In Praise of Prevention,” an animated video designed ... English and French translations of the video are being distributed throughout Togo, Liberia, ...
(Date:2/8/2016)... ... 08, 2016 , ... CURE Media Group , the nation’s leading digital ... Myeloma Heroes Awards event , which will annually honor individuals making heroic contributions in ... The MM Heroes Awards nomination process is officially open through February 17 ...
(Date:2/8/2016)... ... ... is famous for gift giving with flowers, chocolates and other tokens of affection meant to ... more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no ... lives they’ve led and the people they’ve touched. , That’s why Give ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... YORK , Feb. 8, 2016  Labvantage ... today announces its first male sexual enhancement product, ... EnduramenT combines proven ethnobotanicals with a patented biomedical ... nitric oxide, the chemical compound responsible for many ... Forgoing the use ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
Breaking Medicine Technology: